BNP Paribas Financial Markets
UNCY icon

BNP Paribas Financial Markets’s Unicycive Therapeutics UNCY Stock Holding History

BNP Paribas Financial Markets’s Portfolio UNCY Stock Details UNCY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$17.5K Sell
3,734
-115,797
-97% -$854K ﹤0.01% 5289
2026
Q1 		$787K Buy
119,531
+19,789
+20% +$130K ﹤0.01% 3300
2025
Q4 		$576K Buy
99,742
+99,687
+181,249% +$532K ﹤0.01% 3491
2025
Q3 		$240 Buy
+55
New +$240 ﹤0.01% 5372

Other funds holding UNCY

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
DC
Diametric Capital Boston, Massachusetts $948M AUM 47.49% 1-Year Est. Return

BNP Paribas Financial Markets's UNCY Position: Q2 2026 in Review

BNP Paribas Financial Markets reduced its Unicycive Therapeutics (UNCY) stake by 97% in Q2 2026, selling an estimated $854K and leaving 3,734 shares worth $17.5K. The position accounts for ﹤0.01% of the portfolio, ranked #5289.

BNP Paribas Financial Markets first reported a position in UNCY in Q3 2025 and has held it in 4 quarters since. The position peaked at $787K in Q1 2026. 79 funds tracked by Wall St. Rank hold UNCY as of Q2 2026.

  • BNP Paribas Financial Markets held 3,734 shares of Unicycive Therapeutics worth $17.5K as of Q2 2026.
  • BNP Paribas Financial Markets sold 115,797 Unicycive Therapeutics shares in Q2 2026, an estimated $854K.
  • Unicycive Therapeutics made up ﹤0.01% of BNP Paribas Financial Markets's portfolio in Q2 2026, its #5289 holding.
  • BNP Paribas Financial Markets first reported a position in Unicycive Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • BNP Paribas Financial Markets's Unicycive Therapeutics position peaked at $787K in Q1 2026.
  • 79 funds tracked by Wall St. Rank held Unicycive Therapeutics as of Q2 2026.

Based on BNP Paribas Financial Markets's 13F filing for Q2 2026, filed 13 Aug 2026.